Treatment of Recurrent Clostridium Difficile Infection With RBX7455

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (340 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-07-22. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjectsubjectschronicmonthstreatment of
  Phrases that lowered it: inhibitorschemotherapymgproton pumptherapy
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 13.1% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 195 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Sponsor's past trials: 689 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design
• Disease area, infectious disease: Yes (lowers risk) · Disease area
• Allocation: non randomized (lowers risk) · Design
• Blinding: none (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea NCT01925417 · started 2013 · scored riskier than 90% of active trials completed
• ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection NCT04247542 · started 2020 · scored riskier than 64% of active trials completed
• Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection NCT04781387 · started 2021 · scored riskier than 29% of active trials completed
• A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI) NCT04891965 · started 2020 · scored riskier than 54% of active trials completed
• Study of CB-183,315 in Participants With Clostridium Difficile Infection NCT01085591 · started 2010 · scored riskier than 60% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.